Phase 1/2Terminated

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pediatric Subjects

Sponsor
Incyte Corporation (Industry)
Enrollment
2 enrolled
Conditions
Acute Graft-versus-host Disease
Interventions
Itacitinib; Corticosteroids
Ages
children, adults
Registry
NCT03721965, EUCTR2018-002253-30

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate itacitinib in combination with corticosteroids for the treatment of Grades II to IV acute graft-versus-host disease (aGVHD) in steroid-naive pediatric participants.

Primary outcomes

  • Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
  • Phase 1: Cmax of Itacitinib When Administered With Corticosteroids
  • Phase 1: Cmin of Itacitinib When Administered With Corticosteroids
  • Phase 1: Tmax of Itacitinib When Administered With Corticosteroids

History

  1. Last registry update

  2. Results first posted

  3. Primary completion

  4. Started

  5. Registered